Prelude Therapeutics (PRLD) opened Q1 2026 with revenue of US$4.6 million and a net loss of US$10.4 million, translating to a basic EPS loss of US$0.13 as the company continued to invest heavily in its pipeline. Over recent quarters, the company has seen revenue move from US$0 in Q1 2025 to US$6.5 million in Q3 2025 and US$5.6 million in Q4 2025 before landing at US$4.6 million in Q1 2026. Quarterly net losses shifted from US$32.1 million in Q1 2025 to US$10.4 million in the latest period, setting up this update as a key checkpoint on how efficiently that revenue is being converted relative to persistent losses.

See our full analysis for Prelude Therapeutics.

With the headline figures on the table, the next step is to see how these results line up with the widely discussed growth and risk narratives around Prelude Therapeutics, and where the numbers start to challenge those stories.

Losses Ease On Trailing Twelve Month View

• Over the last twelve months, Prelude reported total revenue of US$16.7 million and a net loss of US$77.8 million, compared with a loss of US$99.5 million on US$12.1 million of revenue for the prior trailing period.
• Bulls point out that trailing losses have been shrinking while revenue has risen, and argue this supports their view that earnings can eventually turn around.
  • They highlight that the trailing loss moved from US$124.3 million at one point in 2025 to US$77.8 million by Q1 2026, while trailing revenue lifted from US$7.0 million to US$16.7 million across the same snapshots.
  • That combination is used to support the bullish assumption that margins can improve materially over time, although the business is still firmly loss making today with a Q1 2026 net loss of US$10.4 million.

Bulls argue this earnings trend is just the early stage of a much larger story, and they spell out the upside case in detail at 🐂 Prelude Therapeutics Bull Case.

High P/S Multiple Despite Ongoing Losses

• The stock trades on a P/S of 28x, compared with 9.7x for the wider US biotechs industry and 15.7x for peers, even though the company reported a trailing twelve month loss of US$77.8 million.
• Bears focus on this combination of high sales multiple and continuing losses as a key part of their more cautious view.
  • They point out that the company is not expected to reach profitability within the next three years, which they see as a risk when paying a P/S that is almost 3x the broader industry level.
  • They also flag that shareholders have already been diluted over the past year, so any further capital raises to fund losses could weigh on the per share claim to any future revenue growth.

Skeptics question whether this valuation and dilution history justify the risk profile, and their full case sets out the key pushbacks at 🐻 Prelude Therapeutics Bear Case.

Valuation Models Versus Market Price

• The current share price of US$4.66 sits far below a stated DCF fair value of about US$196.72, while at the same time the company is unprofitable and is forecast to remain unprofitable over the next three years.
• What stands out in the bullish narrative is how this large modelled upside is weighed against the reality of ongoing reported losses.
  • Supporters point to the forecast revenue growth rate of about 55.5% each year and treat the gap between US$4.66 and the DCF fair value as evidence that the market is not pricing in those projections.
  • Cautious investors, by contrast, focus on the fact that losses have accumulated to US$77.8 million over the last twelve months and highlight recent share price volatility as reasons to treat any model based upside with care.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Prelude Therapeutics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With both risks and rewards in play, sentiment on Prelude Therapeutics is clearly mixed. Consider acting promptly, review the numbers for yourself, and weigh the 2 key rewards and 3 important warning signs.

See What Else Is Out There

Prelude Therapeutics is still reporting sizable losses, trades on a P/S that is well above industry levels, and carries valuation and dilution concerns that some investors find uncomfortable.

If that mix of ongoing losses and a rich sales multiple feels too risky, you may want to compare it with 68 resilient stocks with low risk scores while sentiment stays uncertain.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.